Table 2.
Outcomes of 18 series describing hybrid coronary revascularization.
| Author | MACCE (%) |
PRBC (%) |
LITA patency (%) |
Hospital LOS (days) |
TVR (%) |
30-day mortality (%) |
Survival (%) |
|---|---|---|---|---|---|---|---|
| Zenati et al. [17] | 0 (0.0) | 2 (6.5) | 100.0 | 2.7 ± 1.0 | 9.6 | 0.0 | 100.0 |
| Lloyd et al. [18] | 0 (0.0) | 1 (5.6) | 100.0 | 5 ± 1.5 | 0.0 | 0.0 | 100.0 |
| Wittwer et al. [19] | 0 (0.0) | 1 (2.9) | 100.0 | 7.5 ± 4 | NR | 0.0 | 100.0 |
| de Cannière et al. [12] | 0 (0.0) | 0 (0.0) | 100.0 | 6.7 ± 0.7 | 15.0 | 0.0 | 100.0 |
| Riess et al. [20] | 0 (0.0) | 2 (3.5) | 97.2 | 5.7 ± 1.8 | 15.8 | 0.0 | 98.2 |
| Stahl et al. [21] | 0 (0.0) | 16 (29.6) | 100.0 | 3.54 (2–12) | 1.9 | 0.0 | 100.0 |
| Cisowski et al. [22] | 0 (0.0) | 2 (4.0) | 98.0 | 4.4 ± 1.7 | 12.7 | 0.0 | 100.0 |
| Davidavicius et al. [11] | 0 (0.0) | 5 (25.0) | 100.0 | 8.1 ± 1.6 | 0.0 | 0.0 | 100.0 |
| Katz et al. [13] | 1 (3.7) | NR | NR | NR | 29.6 | 0.0 | 100.0 |
| Us et al. [23] | 0 (0.0) | 1 (5.9) | NR | 5.3 ± 1.4 | 17.6 | 0.0 | 100.0 |
| Gilard et al. [6] | 1 (1.4) | 12 (17.1) | NR | NR | 4.3 | 1.4 | 98.6 |
| Kon et al. [7] | 0 (0.0) | NR | 100.0 | 3.7 ± 1.4 | 6.7 | 0.0 | 100.0 |
| Kiaii et al. [14] | 2 (3.4) | 9 (15.5) | 93.0 | 4.3 ± 1.42 | 5.2 | 0.0 | 100.0 |
| Holzhey et al. [24] | 3 (2.6) | NR | NR | NR | 4.3 | 1.7 | 84.8 at 5 years |
| Zhao et al. [25] | 5 (4.5) | NR | NR | 6 (1–97) (median) | NR | 2.6 | NR |
| Delhaye et al. [26] | 1 (5.6) | 2 (11.1) | NR | 10.0 (10.0–11.2) (median) | 5.6 | 0.0 | 100.0 |
| Halkos et al. [27] | 3 (2.0) | 52 (35.4) | NR | 6.6 ± 6.7 | 8.8 | 0.7 | 86.8 at 5 years |
| Hu et al. [28] | 0 (0.0) | 30 (28.8) | NR | 8.2 ± 2.6 | 1.0 | 0.0 | 100.0 |
Unless otherwise indicated, data are expressed as mean ± standard deviation or number (%). MACCE: major adverse cardiac and cerebrovascular events; PRBC: packed red blood cells; LITA: left internal thoracic artery; LOS: length of stay; TVR: target vessel revascularization; NR: not reported.